YusufSJosephPRangarajanS, et al.Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study. Lancet. Epub ahead of print 3 September 2019. DOI: 10.1016/S0140-6736(19)32008-2.
2.
D’AscenziFAnselmiFFiorentiniC, et al.The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology. Eur J Prev Cardiol. Epub ahead of print 6 October 2019. DOI: 10.1177/2047487319874900.
3.
HurriaAJonesLMussHB. Cancer treatment as an accelerated aging process: Assessment, biomarkers, and interventions. Am Soc Clin Oncol Educ B2016; 36: e516–e522.
4.
JonesLWFelsDRWestM, et al.Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prev Res (Phila)2013; 6: 925–938.
5.
StefaniLKlikaRMascheriniG, et al.Effects of a home-based exercise rehabilitation program for cancer survivors. J Sports Med Phys Fitness2019; 59: 846–852.
6.
LipsettABarrettSHarunaF, et al.The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: A systematic review and meta-analysis. Breast2017; 32: 144–155.
7.
CormiePGalvãoDASpryN, et al.Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: A randomised controlled trial. BJU Int2015; 115: 256–266.
8.
LahartIMMetsiosGSNevillAM, et al.Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies. Acta Oncol2015; 54: 635–654.
9.
ScottJMLiNLiuQ, et al.Association of exercise with mortality in adult survivors of childhood cancer. JAMA Oncol2018; 4: 1352–1358.
10.
BrownJCTroxelABKyB, et al.Dose–response effects of aerobic exercise among colon cancer survivors: A randomized phase II trial. Clin Colorectal Cancer2018; 17: 32–40.
11.
PalomoARayRMJohnsonL, et al.Associations between exercise prior to and around the time of cancer diagnosis and subsequent cardiovascular events in women with breast cancer: A women’s health initiatitive (WHI) analysis. J Am Coll Cardiol2017; 69: 1774–1774.
12.
LeeKTripathyDDemark-WahnefriedW, et al.Effect of aerobic and resistance exercise intervention on cardiovascular disease risk in women with early-stage breast cancer. JAMA Oncol2019; 5: 710–714.
13.
AdamsSCDeLoreyDSDavenportMH, et al.Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trial. Cancer2017; 123(: 4057–4065.
14.
KirkhamAAEvesNDShaveRE, et al.The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: A RCT. Breast Cancer Res Treat2018; 167: 719–729.
15.
HowdenEJBigaranABeaudryR, et al.Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. Eur J Prev Cardiol2019; 26: 305–315.
16.
NagyACGulAcsi-BArdosPCserEpZ, et al.Late cardiac effect of anthracycline therapy in physically active breast cancer survivors – a prospective study. Neoplasma2017; 64: 92–100.
17.
JärveläLSSarasteMNiinikoskiH, et al.Home-based exercise training improves left ventricle diastolic function in survivors of childhood ALL: A tissue Doppler and velocity vector imaging study. Pediatr Blood Cancer2016; 63: 1629–1635.
18.
MaiaTNde AraujoGBRTeixeiraJAC, et al.Cardiotoxicity of doxorubicin treatment and physical activity: A systematic review. Int J Cardiovasc Sci2017; 30: 70–80.
19.
HayesSCNewtonRUSpenceRR, et al.The Exercise and Sports Science Australia position statement: Exercise medicine in cancer management. J Sci Med Sport2019; 11: 1175–1199.
20.
ScottJMZaborECSchwitzerE, et al.Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: A systematic review and meta-analysis. J Clin Oncol2018; 36: 2297–2305.
21.
NewtonRUKenfieldSAHartNH, et al.Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL-GAP4): A multicentre, randomised, controlled phase III study protocol. BMJ Open2018; 8: e022899–e022899.
